TNKase

News

Genentech has won FDA approval for its clot-buster TNKase as a treatment for acute ischaemic stroke, after almost abandoning the project in 2023.

Oncology

At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.